Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jul;60(7):978-993.
doi: 10.1038/s41409-025-02570-w. Epub 2025 Apr 19.

Diagnostic accuracy of liver stiffness measurement for the diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (HSCT), the ELASTOVOD STUDY: an investigator-initiated, prospective, multicentre diagnostic clinical trial

Collaborators, Affiliations
Free article
Clinical Trial

Diagnostic accuracy of liver stiffness measurement for the diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (HSCT), the ELASTOVOD STUDY: an investigator-initiated, prospective, multicentre diagnostic clinical trial

Federico Ravaioli et al. Bone Marrow Transplant. 2025 Jul.
Free article

Abstract

Hepatic Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a severe complication following hematopoietic stem cell transplantation (HSCT), traditionally diagnosed based on clinical criteria. This study aimed to evaluate the diagnostic performance of liver stiffness measurement (LSM) as a non-invasive tool for non invasive diagnosis of VOD/SOS. A multicentre clinical trial was conducted in Italy from April 2018 to December 2021, screening 1089 patients across 25 centers. VOD/SOS diagnosis followed established clinical guidelines, and patients underwent comprehensive clinical, laboratory, and imaging evaluations up to +100 days post-HSCT or until VOD/SOS diagnosis. LSM was measured pre-HSCT and on specific post-transplant days (ClinicalTrials.gov: NCT03426358). The study enrolled 774 adults and 167 children. The +100-day incidence of VOD/SOS HSCT was 5.53 and 5.26 in the overall and allo-HSCT population, higher in children (14.3%) than in adults (3.68%). The 100-day overall survival (OS) probability was 89.5% (overall) and 89.0% (allo-HSCT) while one-yr OS 79% and 78%, respectively, with outcomes varying by VOD/SOS occurrence and severity. LSM significantly differed between VOD/SOS patients and non-affected individuals at all post-HSCT time points, correlating with disease severity. A diagnostic algorithm was proposed, achieving ≥95% sensitivity and specificity, with a 6 kPa rule-out and 25 kPa rule-in cut-off, enhanced by the "three-time pre-HSCT rule." Survivors showed declining LSM over time, while non-survivors did not. Fully recovered patients had lower LSM than non-improvers. LSM also distinguished VOD/SOS from other liver complications within +100 days post-HSCT in both adults and children. In conclusion, LSM is a reliable, non-invasive diagnostic tool for VOD/SOS. LSM contribute to differential diagnosis and to treatment response as well. This study underscores the potential of LSM, combined with multidisciplinary expertise, to guide VOD/SOS diagnosis and management in HSCT patients, improving potentially the clinical outcomes.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Federico Ravaioli received speaker fees and travel support from Jazz Pharmaceuticals; Antonio Colecchia speaker fees and travel support from Jazz Pharmaceuticals; Daria Pagliara received speaker fees from Dotcom SRL; Anna Grassi received speaker fees from MSD and travel support from Pfizer and Sanofi; Francesco Barbato has received travel support from Neovii; Lucia Prezioso received speaker fees from Jazz Pharmaceuticals and consulting/advisory board fees from Jazz Pharmaceuticals; Ester Vanni received speaker fees from Jazz Pharmaceuticals; Attilio Olivieri has participated at Advisory Board from Jazz Pharmaceuticals; Mario Delia has received travel support from Jazz Pharmaceuticals; Edoardo Benedetti has received speaker fees from Jazz Pharmaceuticals, Abbvie and AstraZeneca and grant support for expert testimony from Beigene; Cristina Skert received speaker fees from Jazz Pharmaceuticals and Kite; Giovanni Marasco received speaker fees from Echosens; Francesco Quagliarella has received travel support from Jazz Pharmaceuticals; Francesca Bonifazi received research funding, speaker fees and travel support from Jazz Pharmaceuticals, Neovii, Sanofi, Novartis; MSD; Kite Gilead, Jaansen, Takeda; Pfizer; Amgen; Medac.

References

    1. Valla DC, Cazals-Hatem D. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2016;40:378–85. - DOI - PubMed
    1. Mohty M, Malard F, Alaskar AS, Aljurf M, Arat M, Bader P, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). Bone Marrow Transpl. 2023;58:749–54. - DOI
    1. Mohty M, Malard F, Abecasis M, Aerts E, Alaskar AS, Aljurf M, et al. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transpl. 2020;55:485–95. - DOI
    1. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl. 2010;16:157–68. - DOI
    1. Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: A new classification from the European society for blood and marrow transplantation. Bone Marrow Transpl. 2018;53:138–45. - DOI

MeSH terms

Associated data